Related Experiment Video
Updated: Feb 14, 2026

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
Published on: August 20, 2007
Antiplatelet Therapy in Diabetes
Arjun Majithia1, Deepak L Bhatt2
1Division of Cardiovascular Medicine, Lahey Hospital and Medical Center, 41 Burlington Mall Road, Burlington, MA 01805, USA.
Insights
Patients with diabetes mellitus (DM) face higher risks of cardiovascular disease (CVD) due to increased platelet reactivity. Antiplatelet therapies are being investigated to prevent cardiovascular events in this population.
Area of Science:
- Cardiology
- Endocrinology
- Pharmacology
Background:
- Diabetes mellitus (DM) is a major risk factor for cardiovascular disease (CVD).
- Increased platelet reactivity in DM patients elevates atherothrombotic CVD risk.
- Understanding antiplatelet therapy's role in DM is crucial for cardiovascular event prevention.
Purpose of the Study:
- To investigate the role of antiplatelet therapies in patients with diabetes mellitus.
- To explore the impact of these therapies on reducing cardiovascular events.
Main Methods:
- Review of existing literature on antiplatelet agents and diabetes.
- Analysis of clinical trial data concerning cardiovascular outcomes in diabetic patients treated with antiplatelet drugs.
Main Results:
- Data suggests a significant association between enhanced platelet activity and CVD in diabetic individuals.
- Exploration of antiplatelet therapies shows potential in mitigating atherothrombotic events.
Conclusions:
- Antiplatelet therapies represent a promising strategy for managing cardiovascular risk in diabetes mellitus.
- Further research is warranted to optimize antiplatelet treatment protocols for diabetic patients.
Abstract:
Cardiovascular disease (CVD) is a significant cause of morbidity and mortality among patients with diabetes mellitus (DM). Increased platelet reactivity among patients with DM contributes to disproportionately high levels of atherothrombotic CVD. Consequently, there has been tremendous interest in exploring the role of antiplatelet therapies in DM to reduce the development of and frequency of future cardiovascular events.
More Related Videos
10:43Transplantation of Pancreatic Islets Into the Kidney Capsule of Diabetic Mice
Published on: October 31, 2007
11:13Adenoviral Gene Therapy for Diabetic Keratopathy: Effects on Wound Healing and Stem Cell Marker Expression in Human Organ-cultured Corneas and Limbal Epithelial Cells
Published on: April 7, 2016
Related Concept Videos
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Gene Therapy
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Psychoneuroimmunology: Diabetes and Cancer
Group Therapy